<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00147732</url>
  </required_header>
  <id_info>
    <org_study_id>098</org_study_id>
    <secondary_id>CKTO 2000-09</secondary_id>
    <nct_id>NCT00147732</nct_id>
  </id_info>
  <brief_title>Randomized Trial of ARCON in Larynx Cancer</brief_title>
  <official_title>A Multicentre, Randomised, Phase III Clinical Trial Comparing Accelerated Radiotherapy With Accelerated Radiotherapy Plus Carbogen and Nicotinamide (ARCON) in Clinical Stage T2-4 Laryngeal Carcinoma.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dutch Cancer Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Radboud University</source>
  <brief_summary>
    <textblock>
      TITLE:

      A multicentre, randomised, phase III clinical trial comparing accelerated radiotherapy with
      accelerated radiotherapy plus carbogen and nicotinamide (ARCON) in clinical stage T2-4
      laryngeal carcinoma.

      PRIMARY OBJECTIVE:

      Does the addition of carbogen and nicotinamide to a schedule of accelerated radiotherapy in
      patients with clinical stage T2-4 laryngeal carcinoma improve local primary tumour control?
      Definitive analysis will be performed on local control rates at two years after completion of
      radiotherapy.

      SECONDARY OBJECTIVES:

      Does the addition of carbogen and nicotinamide

        -  increase the larynx preservation rate?

        -  increase the regional control rate?

        -  increase the toxicity of accelerated radiotherapy?

        -  improve the overall quality of life?

        -  improve the disease-free survival?

        -  improve the overall survival?

      STUDY DESIGN:

      An open-label, randomised clinical trial assigning patients in a 1:1 ratio to one of the
      following treatment arms:

        -  accelerated radiotherapy

        -  accelerated radiotherapy plus carbogen and nicotinamide

      PATIENT CHARACTERISTICS AND NUMBER:

      344 patients with clinical T2-4 laryngeal carcinoma

      MEASUREMENTS:

        -  time to local failure

        -  time to regional failure

        -  survival with functional larynx

        -  overall and disease-free survival

        -  frequency and severity of complications related to radiotherapy and carbogen and
           nicotinamide

        -  quality of life assessment
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2001</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">February 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Local control</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>larynx preservation</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>regional control rate</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>toxicity</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>disease-free survival</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>improve the overall survival</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">345</enrollment>
  <condition>Larynx Carcinoma</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Accelerated radiotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ARCON</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Accelerated radiotherapy</intervention_name>
    <description>68 Gy over 5.5 weeks</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>ARCON</intervention_name>
    <description>68 Gy over 5.5 weeks Carbogen: 98% oxygen plus 2% carbon dioxide Nicotinamide 60 mg/kg daily</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pathological confirmed squamous cell carcinoma of the larynx.

          -  TNM-classification (UICC 1997, appendix I):

          -  T3-4 glottic or supraglottic carcinoma

          -  T2 glottic carcinoma with impaired cord mobility or subglottic extension

          -  T2 supraglottic carcinoma with invasion of mucosa of base of tongue or vallecula or
             invasion of the medial wall of the piriform sinus.

          -  any N-stage, M0.

          -  WHO performance status 0 or 1 (appendix II).

          -  Age &gt; 18 years.

          -  Written informed consent.

          -  Quality of life questionnaire completed.

        Exclusion Criteria:

          -  Prior or concurrent treatment for this tumour.

          -  Severe stridor and adequate debulking of airway not possible.

          -  Impaired renal function: serum creatinine above upper normal limit.

          -  Use of nefrotoxic medication (including ACE-inhibitors) that cannot be discontinued
             for the duration of the radiation treatment.

          -  Impaired hepatic function: ASAT and ALAT more than 1.5 times the upper normal limit.

          -  Use of anti-convulsants that cannot be discontinued for the duration of the radiation
             treatment.

          -  History of malignancy during the previous 5 years except basal cell carcinoma of skin,
             carcinoma in situ of the cervix, or superficial bladder neoplasm (pTa).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Johannes HA Kaanders, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radboud University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Free University Medical Centre</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Centre Groningen</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leids University Medical Centre</name>
      <address>
        <city>Leiden</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maastro Clinic</name>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radboud University Nijmegen Medical Centre</name>
      <address>
        <city>Nijmegen</city>
        <zip>6500 HB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical centre Utrecht</name>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Vernon Hospital</name>
      <address>
        <city>Northwood</city>
        <state>Middlesex</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 6, 2005</study_first_submitted>
  <study_first_submitted_qc>September 6, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 7, 2005</study_first_posted>
  <last_update_submitted>May 6, 2015</last_update_submitted>
  <last_update_submitted_qc>May 6, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 7, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>larynx carcinoma</keyword>
  <keyword>radiotherapy</keyword>
  <keyword>carbogen</keyword>
  <keyword>nicotinamide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Laryngeal Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Niacinamide</mesh_term>
    <mesh_term>Niacin</mesh_term>
    <mesh_term>Nicotinic Acids</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

